tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ITRM Stock Latest News

Iterum Therapeutics provides market access update
The FlyIterum Therapeutics provides market access update
27d ago
ITRM
Iterum Therapeutics provides business update
PremiumThe Fly
Iterum Therapeutics provides business update
1M ago
ITRM
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
PremiumCompany Announcements
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
1M ago
8K
ITRM
Buy Rating Affirmed for Iterum Therapeutics Amid Strategic Launch of ORLYNVAH and Strong Market Positioning
PremiumRatings
Buy Rating Affirmed for Iterum Therapeutics Amid Strategic Launch of ORLYNVAH and Strong Market Positioning
1M ago
ITRM
Iterum Therapeutics says ORLYNVAH access ‘continues to grow’
PremiumThe Fly
Iterum Therapeutics says ORLYNVAH access ‘continues to grow’
2M ago
ITRM
Iterum Therapeutics receives 510(k) clearance for Susceptibility Test Disc
PremiumThe FlyIterum Therapeutics receives 510(k) clearance for Susceptibility Test Disc
2M ago
ITRM
Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
Premium
Ratings
Buy Rating Maintained for Iterum Therapeutics Despite Initial Challenges, Driven by Unique Market Position of ORLYNVAH
2M ago
ITRM
Iterum Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Iterum Therapeutics Reports Q3 2025 Financial Results
2M ago
ITRM
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
PremiumCompany Announcements
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
2M ago
ITRM
Iterum Therapeutics sees cash runway into 2Q26
PremiumThe Fly
Iterum Therapeutics sees cash runway into 2Q26
2M ago
ITRM
Iterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M
PremiumThe Fly
Iterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M
2M ago
ITRM
Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year
PremiumThe Fly
Iterum Therapeutics reports Q3 non-GAAP EPS (16c) vs. (24c) last year
2M ago
ITRM
Is ITRM a Buy, Before Earnings?
PremiumPre-EarningsIs ITRM a Buy, Before Earnings?
3M ago
ITRM
Iterum Therapeutics Advances Adolescent Antibiotic Trial: Key Insights for Investors
Premium
Company Announcements
Iterum Therapeutics Advances Adolescent Antibiotic Trial: Key Insights for Investors
3M ago
ITRM
Iterum Therapeutics Announces $20M Share Offering
Premium
Company Announcements
Iterum Therapeutics Announces $20M Share Offering
3M ago
8K
ITRM
Iterum Therapeutics sees cash runway into 2026
PremiumThe Fly
Iterum Therapeutics sees cash runway into 2026
4M ago
ITRM
Iterum Therapeutics Faces Shareholder Pushback on Key Proposals
PremiumCompany Announcements
Iterum Therapeutics Faces Shareholder Pushback on Key Proposals
4M ago
8K
ITRM
Iterum Therapeutics Faces Nasdaq Delisting Notice
PremiumCompany Announcements
Iterum Therapeutics Faces Nasdaq Delisting Notice
5M ago
8K
ITRM
Iterum Therapeutics Launches New Antibiotic ORLYNVAH
PremiumCompany Announcements
Iterum Therapeutics Launches New Antibiotic ORLYNVAH
5M ago
8K
ITRM
Iterum Therapeutics announces U.S. commercial launch of ORLYNVAH
PremiumThe FlyIterum Therapeutics announces U.S. commercial launch of ORLYNVAH
5M ago
ITRM
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
Premium
Company Announcements
Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges
6M ago
ITRM
Buy Rating for Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch
Premium
Ratings
Buy Rating for Iterum Therapeutics: Strategic Positioning and Growth Potential with ORLYNVAH Launch
6M ago
ITRM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >